Abstract:BACKGROUND & AIMS Inflammatory bowel disease (IBD) is a complex and relapsing inflammatory disease, and patients with IBD exhibit a higher risk of developing colorectal cancer (CRC). Epithelial barrier disruption is one of the major causes of IBD in which epigenetic modulation is pivotal. However, the epigenetic mechanisms underlying the epithelial barrier integrity regulation remain largely unexplored. Here, we investigated how SETD2, an epigenetic modifier, maintains intestinal epithelial homeostasis and attenuates colonic inﬂammation and tumorigenesis. METHODS GEO public database and IBD tissues were used to investigate the clinical relevance of SETD2 in IBD. To define a role of SETD2 in the colitis, we generated mice with epithelium-specific deletion of Setd2 ( Setd2 Vil-KO mice). Acute colitis was induced by 2% dextran sodium sulfate (DSS), and colitis-associated CRC was induced by injecting azoxymethane (AOM), followed by three cycles of 2% DSS treatments. Colon tissues were collected from mice and analyzed by histology, immunohistochemistry and immunoblots. Organoids were generated from Setd2Vil-KO and control mice, and were stained with 7-AAD to detect apoptosis. A fluorescent probe, 2′,7′-dichlorodihydroﬂuorescein diacetate (H2DCFDA), was used to detect the levels of ROS in intestinal epithelial cells (IECs) isolated from the two types of mice. RNA-seq and H3K36me3 ChIP-seq analyses were performed to identify the mis-regulated genes modulated by SETD2. Results were validated in functional rescue experiments by N-acetyl-l-cysteine (NAC) treatment and transgenes expression in IECs. RESULTS SETD2 expression became decreased in IBD patients and DSS-treated colitis mice. Setd2 Vil-KO mice displayed abnormal loss of mucus-producing goblet cells and antimicrobial peptide (AMP)-producing Paneth cells, and exhibited pre-mature intestinal inflammation development. Consistent with the reduced SETD2 expression in IBD patients, Setd2 Vil-KO mice showed increased susceptibility to DSS-induced colitis, accompanied by more severe epithelial barrier disruption and markedly increased intestinal permeability that subsequently facilitated inﬂammation-associated CRC. Mechanistically, deletion of Setd2 resulted in excess reactive oxygen species (ROS), which led to cellular apoptosis and defects in barrier integrity. NAC treatment in Setd2 Vil-KO mice rescued epithelial barrier injury and apoptosis. Importantly, Setd2 depletion led to excess ROS by directly down-regulating antioxidant genes that inhibit ROS reaction. Moreover, overexpression of antioxidant PRDX6 in Setd2 Vil-KO IECs largely alleviated the overproductions of ROS and improved the cellular survival. CONCLUSIONS Deficiency of Setd2 specifically in the intestine aggravates epithelial barrier disruption and inflammatory response in colitis via a mechanism dependent on oxidative stress. Thus, our results highlight an epigenetic mechanism by which Setd2 modulates oxidative stress to regulate intestinal epithelial homeostasis. SETD2 might therefore be a pivotal regulator that maintains the homeostasis of the intestinal mucosal barrier. ### Competing Interest Statement The authors have declared no competing interest. * AMP : antimicrobial peptide AOM : azoxymethane 7-AAD : 7- aminoactinomycin D CD : Crohn’s disease CRC : colorectal cancer DSS : dextran sodium sulfate GO : gene ontology H2DCFDA : 2′,7′-dichlorodihydroﬂuorescein diacetate H3K36 : histone H3 lysine 36 IBD : inflammatory bowel disease IEC : intestinal epithelial cell NAC : N-acetyl-l-cysteine 8-OHdG : 8-oxo-2’- deoxyguanosine PRDX : peroxiredoxin ROS : reactive oxygen species RT-qPCR : Real-Time quantitative PCR UC : ulcerative colitis ZO-1 : tight junction protein 1.

Setd2 determines distinct properties of intestinal ILC3 subsets to regulate intestinal immunity

Setd2 Regulates Quiescence and Differentiation of Adult Hematopoietic Stem Cells by Restricting RNA Polymerase II Elongation.

Methyltransferase Setd2 Prevents T Cell-Mediated Autoimmune Diseases Via Phospholipid Remodeling

Loss of Setd2 Associates with Aberrant Microrna Expression and Contributes to Inflammatory Bowel Disease Progression in Mice.

Differential Role of Id2 in the Group 3 Innate Lymphoid Cells for the Development of Different Gut Associated Lymphoid Tissues

The histone methyltransferase SETD2 modulates oxidative stress to attenuate experimental colitis

SETDB1 is required for intestinal epithelial differentiation and the prevention of intestinal inflammation

Setdb1 regulates proper differentiation of adult intestinal stem cells via restraining permissive chromatin structure and transcriptional variability

The Histone Methyltransferase Setd2 is Indispensable for V(D)J Recombination

Setd1a regulates progenitor B-cell-to-precursor B-cell development through histone H3 lysine 4 trimethylation and Ig heavy-chain rearrangement.

Innate Lymphoid Cells Control Early Colonization Resistance against Intestinal Pathogens through ID2-Dependent Regulation of the Microbiota

Histone Methyltransferase SETD2 Modulates Alternative Splicing to Inhibit Intestinal Tumorigenesis.

The Histone Methyltransferase SETD2 Modulates Oxidative Stress to Attenuate Colonic Inflammation and Tumorigenesis in Mice

The Transcription Factor ThPOK Regulates ILC3 Lineage Homeostasis and Function During Intestinal Infection.

PD-1 regulates ILC3-driven intestinal immunity and homeostasis

The histone demethylase Kdm6b regulates the maturation and cytotoxicity of TCRαβ+CD8αα+ intestinal intraepithelial lymphocytes

Sirtuin 6 inhibits group 3 innate lymphoid cell function and gut immunity by suppressing IL-22 production

Cdx2 regulates immune cell infiltration in the intestine

The histone demethylase Kdm6b regulates the maturation and cytotoxicity of TCR<SUP>+</SUP>CD8<SUP>+</SUP> intestinal intraepithelial lymphocytes

Innate Lymphoid Cells Support Regulatory T Cells in the Intestine Through Interleukin-2.

Loss of H3K36 Methyltransferase SETD2 Impairs V(D)J Recombination During Lymphoid Development.